anayamalik, Author at European Medical Journal - Page 80 of 83

RSV Threatens 50% of Healthy Infants Under 1

A new study reveals that over half of healthy U.S. infants contract respiratory syncytial virus in their first year, with 44.1% developing lower respiratory tract infections.

Is Preoperative Radiotherapy the Key to Glioblastoma Survival?

Preoperative radiotherapy may significantly enhance survival rates for glioblastoma, a particularly aggressive brain cancer.

Childhood Obesity’s Unexpected Impact on Skin

A strong link between childhood obesity and the development of immune-mediated skin diseases has been highlighted in new research.

Cancer Misinformation Online: A Growing Threat for Doctors

One-third of popular social media articles about breast, colorectal, lung, and prostate cancer contained misleading or harmful information, according to a new study.

One-Third of Adults Hesitant to Vaccinate This Fall

A national survey highlights rising vaccine hesitancy this flu season, with 37% of adults planning to skip flu and COVID-19 vaccines despite CDC recommendations.

Higher Secukinumab Dose Fails to Improve Outcomes

New study found that increasing secukinumab dosage to 300 mg provides no significant benefit for ankylosing spondylitis patients who did not respond to 150 mg.

Inherited Genetic Mutations Tied to Early-Onset Myeloma

Inherited BRCA mutations may sharply increase the risk of early-onset multiple myeloma, according to new research.

Cannabis and Psychedelic Use Reaches Historic Highs

Cannabis and hallucinogen use among adults continued to reach historic highs in 2023, according to the latest findings from the NIH-supported Monitoring the Future (MTF) survey.

Rethinking Alzheimer's: Increasing Amyloid-β42 Slows Disease Progression

Researchers from the University of Cincinnati, Ohio, suggest that increasing levels of the brain protein amyloid-β 42 may slow cognitive decline in Alzheimer’s disease.

New Biologic for Atopic Dermatitis Receives FDA-Approval

Approval has been granted by the FDA for lebrikizumab-lbkz in treating moderate to severe atopic dermatitis in patients aged 12 and older.